{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:18:48Z","timestamp":1788963528697,"version":"build-2803163510"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100010621","name":"Uniwersytet Medyczny w Lublinie","doi-asserted-by":"publisher","award":["DS 725\/2024-2026"],"award-info":[{"award-number":["DS 725\/2024-2026"]}],"id":[{"id":"10.13039\/501100010621","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"DOI":"10.1007\/s43440-026-00898-8","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:32:02Z","timestamp":1788957122000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Interactions of ACEA and WIN 55,212-2 mesylate with temozolomide and cisplatin in neuroblastoma and glioblastoma cell lines: an isobolographic analysis"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5358-8889","authenticated-orcid":false,"given":"Katarzyna","family":"Za\u0142uska-Ogryzek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7099-1968","authenticated-orcid":false,"given":"Paula","family":"Wr\u00f3blewska-\u0141uczka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7075-1051","authenticated-orcid":false,"given":"Agnieszka","family":"G\u00f3ralczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7296-2802","authenticated-orcid":false,"given":"Micha\u0142","family":"Chojnacki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3059-0393","authenticated-orcid":false,"given":"Jarogniew J.","family":"\u0141uszczki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"898_CR1","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1001\/jama.2023.0023","volume":"329","author":"LR Schaff","year":"2023","unstructured":"Schaff LR, Mellinghoff IK. Glioblastoma and Other Primary Brain Malignancies in Adults: A Review. JAMA. 2023;329:574\u201387.","journal-title":"JAMA"},{"key":"898_CR2","first-page":"vdae028","volume":"6","author":"N Nabian","year":"2024","unstructured":"Nabian N, Ghalehtaki R, Zeinalizadeh M, Bala\u00f1a C, Jablonska PA. State of the neoadjuvant therapy for glioblastoma multiforme-Where do we stand? Neurooncol Adv. 2024;6:vdae028.","journal-title":"Neurooncol Adv"},{"key":"898_CR3","doi-asserted-by":"crossref","unstructured":"Fan L, Wu H, Zhang Y, Yu B, Feng J, Du Y, et al. The efficacy of combination therapy versus monotherapy in patients with glioblastoma with abnormal epidermal growth factor receptor (EGFR) genes, a systematic review and network meta-analysis. Neuroscience. 2026.","DOI":"10.1016\/j.neuroscience.2025.12.064"},{"key":"898_CR4","first-page":"5","volume":"11","author":"M Price","year":"2024","unstructured":"Price M, Ryan K, Shoaf ML, Neff C, Iorgulescu JB, Landi DB, et al. Childhood, adolescent, and adult primary brain and central nervous system tumor statistics for practicing healthcare providers in neuro-oncology, CBTRUS 2015\u20132019. Neurooncol Pract. 2024;11:5\u201325.","journal-title":"Neurooncol Pract"},{"key":"898_CR5","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1002\/1878-0261.13678","volume":"18","author":"J Weller","year":"2024","unstructured":"Weller J, Potthoff AL, Zeyen T, Schaub C, Duffy C, Schneider M, et al. Current status of precision oncology in adult glioblastoma. Mol Oncol. 2024;18:2927\u201350.","journal-title":"Mol Oncol"},{"key":"898_CR6","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s11060-024-04881-2","volume":"171","author":"A Badani","year":"2025","unstructured":"Badani A, Ozair A, Khasraw M, Woodworth GF, Tiwari P, Ahluwalia MS, et al. Immune checkpoint inhibitors for glioblastoma: emerging science, clinical advances, and future directions. J Neurooncol. 2025;171:531\u201347.","journal-title":"J Neurooncol"},{"key":"898_CR7","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1007\/s12672-025-03807-2","volume":"16","author":"M Nourizadeh","year":"2025","unstructured":"Nourizadeh M, Mounesyar SM, Movahhed MS, Alipour K, Zekavatbakhsh R, Hoseinzadeh M, et al. Current strategies and novel immunotherapeutic approaches for overcoming immune resistance in glioblastoma. Discov Oncol. 2025;16:1952.","journal-title":"Discov Oncol"},{"key":"898_CR8","first-page":"Cd012532","volume":"1","author":"SM de Melo","year":"2025","unstructured":"de Melo SM, Elias Nunes da Silva ME, Torloni MR, Riera R, De Cicco K, Latorraca CO, et al. Anti-PD-1 and anti-PD-L1 antibodies for glioma. Cochrane Database Syst Rev. 2025;1:Cd012532.","journal-title":"Cochrane Database Syst Rev"},{"key":"898_CR9","doi-asserted-by":"publisher","first-page":"e70160","DOI":"10.1002\/prp2.70160","volume":"13","author":"FA Javid","year":"2025","unstructured":"Javid FA, Belancic A, Kwok MK, Lam YW. Recent Advances in the Therapeutic Potential of Cannabinoids Against Gliomas: A Systematic Review (2022\u20132025). Pharmacol Res Perspect. 2025;13:e70160.","journal-title":"Pharmacol Res Perspect"},{"key":"898_CR10","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s43440-024-00580-x","volume":"76","author":"B Buchalska","year":"2024","unstructured":"Buchalska B, Kami\u0144ska K, Owe-Larsson M, Cudnoch-J\u0119drzejewska A. Cannabinoids in the treatment of glioblastoma. Pharmacol Rep. 2024;76:223\u201334.","journal-title":"Pharmacol Rep"},{"key":"898_CR11","doi-asserted-by":"publisher","first-page":"e76918","DOI":"10.1371\/journal.pone.0076918","volume":"8","author":"M Solinas","year":"2013","unstructured":"Solinas M, Massi P, Cinquina V, Valenti M, Bolognini D, Gariboldi M, et al. Cannabidiol, a non-psychoactive cannabinoid compound, inhibits proliferation and invasion in U87-MG and T98G glioma cells through a multitarget effect. PLoS ONE. 2013;8:e76918.","journal-title":"PLoS ONE"},{"key":"898_CR12","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1158\/1535-7163.MCT-10-0688","volume":"10","author":"S Torres","year":"2011","unstructured":"Torres S, Lorente M, Rodr\u00edguez-Forn\u00e9s F, Hern\u00e1ndez-Tiedra S, Salazar M, Garc\u00eda-Taboada E, et al. A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol Cancer Ther. 2011;10:90\u2013103.","journal-title":"Mol Cancer Ther"},{"key":"898_CR13","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1124\/jpet.103.061002","volume":"308","author":"P Massi","year":"2004","unstructured":"Massi P, Vaccani A, Ceruti S, Colombo A, Abbracchio MP, Parolaro D. Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. J Pharmacol Exp Ther. 2004;308:838\u201345.","journal-title":"J Pharmacol Exp Ther"},{"key":"898_CR14","doi-asserted-by":"crossref","unstructured":"Hohmann T, Feese K, Greither T, Ghadban C, J\u00e4ger V, Dehghani F, et al. Synthetic cannabinoids influence the invasion of glioblastoma cell lines in a cell- and receptor-dependent manner. Cancers. 2019;11.","DOI":"10.3390\/cancers11020161"},{"key":"898_CR15","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1080\/19336918.2016.1183867","volume":"11","author":"T Hohmann","year":"2017","unstructured":"Hohmann T, Grabiec U, Ghadban C, Feese K, Dehghani F. The influence of biomechanical properties and cannabinoids on tumor invasion. Cell Adh Migr. 2017;11:54\u201367.","journal-title":"Cell Adh Migr"},{"key":"898_CR16","doi-asserted-by":"crossref","unstructured":"Taha S, Aljishi M, Sultan A, Sridharan K, Taurin S, Greish K, et al. Enhanced cytotoxicity and receptor modulation by SMA-WIN 55,212-2 micelles in glioblastoma cells. Int J Mol Sci. 2025;26.","DOI":"10.3390\/ijms26104544"},{"key":"898_CR17","doi-asserted-by":"publisher","first-page":"177775","DOI":"10.1016\/j.ejphar.2025.177775","volume":"1001","author":"K Za\u0142uska-Ogryzek","year":"2025","unstructured":"Za\u0142uska-Ogryzek K, Wr\u00f3blewska-\u0141uczka P, G\u00f3ralczyk A, Luszczki JJ. Antiproliferative effects of arvanil, olvanil and LY2183240 on human neuroblastoma and glioblastoma cell lines and their in vitro interactions with cisplatin and temozolomide: an isobolographic analysis. Eur J Pharmacol. 2025;1001:177775.","journal-title":"Eur J Pharmacol"},{"key":"898_CR18","doi-asserted-by":"publisher","first-page":"111392","DOI":"10.1016\/j.cbi.2025.111392","volume":"408","author":"K Za\u0142uska-Ogryzek","year":"2025","unstructured":"Za\u0142uska-Ogryzek K, Wr\u00f3blewska-\u0141uczka P, G\u00f3ralczyk A, \u0141uszczki JJ. Isobolographic interactions of cannabidiol and AM 1172 with cisplatin in human neuroblastoma and glioblastoma cell lines: An in vitro study. Chem Biol Interact. 2025;408:111392.","journal-title":"Chem Biol Interact"},{"key":"898_CR19","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1007\/s12672-024-01356-8","volume":"15","author":"MB Faiz","year":"2024","unstructured":"Faiz MB, Naeem F, Irfan M, Aslam MA, Estevinho LM, Ate\u015f\u015fahin DA, et al. Exploring the therapeutic potential of cannabinoids in cancer by modulating signaling pathways and addressing clinical challenges. Discov Oncol. 2024;15:490.","journal-title":"Discov Oncol"},{"key":"898_CR20","doi-asserted-by":"crossref","unstructured":"Dasram MH, Naidoo P, Walker RB, Khamanga SM. Targeting the endocannabinoid system present in the glioblastoma tumour microenvironment as a potential anti-cancer strategy. Int J Mol Sci. 2024;25.","DOI":"10.3390\/ijms25031371"},{"key":"898_CR21","doi-asserted-by":"crossref","unstructured":"Kis B, Ifrim FC, Buda V, Avram S, Pavel IZ, Antal D, et al. Cannabidiol-from plant to human body: a promising bioactive molecule with multi-target effects in cancer. Int J Mol Sci. 2019;20.","DOI":"10.3390\/ijms20235905"},{"key":"898_CR22","doi-asserted-by":"crossref","unstructured":"Bonomo G, Certo F, Grasso E, Fiuman\u00f2 G, Barbagallo D, Caltabiano R, et al. Efficacy and safety of prolonged adjuvant temozolomide treatment in glioblastoma: prospective study of 81 patients undergoing up to 101 cycles of treatment. Brain Sci. 2025;15.","DOI":"10.3390\/brainsci15050428"},{"key":"898_CR23","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s11060-021-03900-w","volume":"158","author":"IM Germano","year":"2022","unstructured":"Germano IM, Ziu M, Wen P, Ormond DR, Olson JJ. Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of cytotoxic chemotherapy and other cytotoxic therapies in the management of progressive glioblastoma in adults. J Neurooncol. 2022;158:225\u201353.","journal-title":"J Neurooncol"},{"key":"898_CR24","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0360-3016(99)00060-7","volume":"44","author":"L Kleinberg","year":"1999","unstructured":"Kleinberg L, Grossman SA, Piantadosi S, Zeltzman M, Wharam M. The effects of sequential versus concurrent chemotherapy and radiotherapy on survival and toxicity in patients with newly diagnosed high-grade astrocytoma. Int J Radiat Oncol Biol Phys. 1999;44:535\u201343.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"898_CR25","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1080\/10937404.2024.2326679","volume":"27","author":"VA de Oliveira","year":"2024","unstructured":"de Oliveira VA, Negreiros HA, de Sousa IGB, Farias Mendes LK, Alves Damaceno Do Lago JP, Alves de Sousa A, et al. Application of nanoformulations as a strategy to optimize chemotherapeutic treatment of glioblastoma: a systematic review. J Toxicol Environ Health B Crit Rev. 2024;27:131\u201352.","journal-title":"J Toxicol Environ Health B Crit Rev"},{"key":"898_CR26","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1615\/IntJMedMushr.v13.i2.50","volume":"13","author":"MK Lemieszek","year":"2011","unstructured":"Lemieszek MK, Langner E, Kaczor J, Kandefer-Szersze\u0144 M, Sanecka B, Mazurkiewicz W, et al. Anticancer effects of fraction isolated from fruiting bodies of Chaga medicinal mushroom, Inonotus obliquus (Pers.:Fr.) Pil\u00e1t (Aphyllophoromycetideae): in vitro studies. Int J Med Mushrooms. 2011;13:131\u201343.","journal-title":"Int J Med Mushrooms"},{"key":"898_CR27","doi-asserted-by":"crossref","unstructured":"Andres-Mach M, Szewczyk A, Zagaja M, Szala-Rycaj J, Lemieszek MK, Maj M, et al. Preclinical assessment of a new hybrid compound C11 efficacy on neurogenesis and cognitive functions after pilocarpine induced status epilepticus in mice. Int J Mol Sci. 2021;22.","DOI":"10.3390\/ijms22063240"},{"key":"898_CR28","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0031-6997(25)00026-2","volume":"41","author":"MC Berenbaum","year":"1989","unstructured":"Berenbaum MC. What is synergy? Pharmacol Rev. 1989;41:93\u2013141.","journal-title":"Pharmacol Rev"},{"key":"898_CR29","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1124\/jpet.104.067264","volume":"310","author":"Y Grabovsky","year":"2004","unstructured":"Grabovsky Y, Tallarida RJ. Isobolographic analysis for combinations of a full and partial agonist: curved isoboles. J Pharmacol Exp Ther. 2004;310:981\u20136.","journal-title":"J Pharmacol Exp Ther"},{"key":"898_CR30","doi-asserted-by":"publisher","first-page":"91","DOI":"10.26444\/jpccr\/210907","volume":"19","author":"JJ \u0141uszczki","year":"2025","unstructured":"\u0141uszczki JJ, B\u0142aszkiewicz-Tyniec A, Ga\u0142\u0119ziowska E, Kowalik A, Krajewska I. Two isobolographic approaches in the evaluation of drug-drug interaction for non-parallel concentration-response curves in an in vitro study. J Pre-Clinical Clin Res. 2025;19:91\u20135.","journal-title":"J Pre-Clinical Clin Res"},{"key":"898_CR31","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s12640-018-9944-9","volume":"35","author":"MN Huizenga","year":"2019","unstructured":"Huizenga MN, Forcelli PA. Neuroprotective Action of the CB1\/2 Receptor Agonist, WIN 55,212-2, against DMSO but Not Phenobarbital-Induced Neurotoxicity in Immature Rats. Neurotox Res. 2019;35:173\u201382.","journal-title":"Neurotox Res"},{"key":"898_CR32","doi-asserted-by":"crossref","unstructured":"Peng B, Yang Q, Liu RBJ, Akbar Y, Song M. BJ, Role of alcohol drinking in alzheimer\u2019s disease, Parkinson\u2019s disease, and amyotrophic lateral sclerosis. Int J Mol Sci. 2020;21.","DOI":"10.3390\/ijms21072316"},{"key":"898_CR33","doi-asserted-by":"crossref","unstructured":"Wr\u00f3blewska-\u0141uczka P, Grabarska A, Florek-\u0141uszczki M, Plewa Z, \u0141uszczki JJ. Synergy, additivity, and antagonism between cisplatin and selected coumarins in human melanoma cells. Int J Mol Sci. 2021;22.","DOI":"10.3390\/ijms22020537"},{"key":"898_CR34","doi-asserted-by":"crossref","unstructured":"Krasowska D, Wr\u00f3blewska-\u0141uczka P, Chojnacki M, Za\u0142uska-Ogryzek K, Kurzepa J, \u0141uszczki JJ. Rasagiline inhibits human melanoma cell viability and interacts synergistically with mitoxantrone and antagonistically with cisplatin-in vitro isobolographic studies. Cancers. 2025;17.","DOI":"10.3390\/cancers17152563"},{"key":"898_CR35","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0022-3565(25)03549-9","volume":"96","author":"JT Litchfield Jr","year":"1949","unstructured":"Litchfield JT Jr., Wilcoxon F. A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther. 1949;96:99\u2013113.","journal-title":"J Pharmacol Exp Ther"},{"key":"898_CR36","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.tox.2017.04.013","volume":"385","author":"M Almada","year":"2017","unstructured":"Almada M, Costa L, Fonseca BM, Amaral C, Teixeira N, Correia-da-Silva G. The synthetic cannabinoid WIN-55,212 induced-apoptosis in cytotrophoblasts cells by a mechanism dependent on CB1 receptor. Toxicology. 2017;385:67\u201373.","journal-title":"Toxicology"},{"key":"898_CR37","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1007\/s43440-025-00784-9","volume":"77","author":"JJ \u0141uszczki","year":"2025","unstructured":"\u0141uszczki JJ, Gustaw-Rothenberg K, Florek-\u0141uszczki M. Log-probit accompanied with Tallarida and Chou-Talalay-Martin methods in an isobolographic analysis of interactions between two antiseizure medications - a comparative study. Pharmacol Rep. 2025;77:1760\u20137.","journal-title":"Pharmacol Rep"},{"key":"898_CR38","doi-asserted-by":"publisher","first-page":"9191","DOI":"10.1002\/0471141755.ph0919s72","volume":"72","author":"RJ Tallarida","year":"2016","unstructured":"Tallarida RJ. Drug Combinations: Tests and Analysis with Isoboles. Curr protocols Pharmacol. 2016;72:9191\u20139.","journal-title":"Curr protocols Pharmacol"},{"key":"898_CR39","doi-asserted-by":"publisher","DOI":"10.1201\/9781420036107","volume-title":"Drug synergism and dose-effect data analysis","author":"RJ Tallarida","year":"2000","unstructured":"Tallarida RJ. Drug synergism and dose-effect data analysis. New York: Chapman and Hall\/CRC; 2000."},{"key":"898_CR40","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1124\/jpet.112.193474","volume":"342","author":"RJ Tallarida","year":"2012","unstructured":"Tallarida RJ. Revisiting the isobole and related quantitative methods for assessing drug synergism. J Pharmacol Exp Ther. 2012;342:2\u20138.","journal-title":"J Pharmacol Exp Ther"},{"key":"898_CR41","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12964-021-00758-3","volume":"19","author":"MT Longhi","year":"2021","unstructured":"Longhi MT, Silva LE, Pereira M, Magalh\u00e3es M, Reina J, Vitorino FNL, et al. PI3K-AKT, JAK2-STAT3 pathways and cell-cell contact regulate maspin subcellular localization. Cell Commun Signal. 2021;19:86.","journal-title":"Cell Commun Signal"},{"key":"898_CR42","doi-asserted-by":"crossref","unstructured":"Qiu L, Fei Y, Ding J, Shi K, Luo J, Zhu Y et al. Unraveling the molecular mechanisms of glioma recurrence: a study integrating single-cell and spatial transcriptomics. Ann Clin Transl Neurol. 2026.","DOI":"10.1002\/acn3.70306"},{"key":"898_CR43","doi-asserted-by":"publisher","first-page":"5527","DOI":"10.1038\/s41598-018-23592-z","volume":"8","author":"M Mettang","year":"2018","unstructured":"Mettang M, Meyer-Pannwitt V, Karpel-Massler G, Zhou S, Carragher NO, F\u00f6hr KJ, et al. Blocking distinct interactions between Glioblastoma cells and their tissue microenvironment: A novel multi-targeted therapeutic approach. Sci Rep. 2018;8:5527.","journal-title":"Sci Rep"},{"key":"898_CR44","doi-asserted-by":"crossref","unstructured":"Delgado-Miranda AL, Gomez-Flores R, Rodr\u00edguez-Garza NE, P\u00e9rez-Gonz\u00e1lez O, Tamez-Guerra P, Caballero-Hern\u00e1ndez D, et al. In vitro anti-glioblastoma activity of Echinocereus engelmannii- and Echinocereus pectinatus-associated bacterial endophyte extracts. Life (Basel). 2025;15.","DOI":"10.3390\/life15040519"},{"key":"898_CR45","doi-asserted-by":"crossref","unstructured":"Ferreira C, Francisco IF, Junqueira MM, Tavares DC, Suzart LR, de Carvalho MG, et al. Chemical composition and selective cytotoxic activity of Euphorbia leucocephala essential oil. Nat Prod Res. 2025:1\u20137.","DOI":"10.1080\/14786419.2025.2583338"},{"key":"898_CR46","doi-asserted-by":"publisher","first-page":"e70294","DOI":"10.1002\/cncr.70294","volume":"132","author":"MJ Monroy-Iglesias","year":"2026","unstructured":"Monroy-Iglesias MJ, O\u2019Connell K, Bhimani J, Blinder VS, Burganowski-Doud RP, Ergas IJ, et al. Initial chemotherapy dose reductions and subsequent treatment delivery in stage I-IIIA breast cancer. Cancer. 2026;132:e70294.","journal-title":"Cancer"},{"key":"898_CR47","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0009-3084(00)00187-0","volume":"108","author":"AC Howlett","year":"2000","unstructured":"Howlett AC, Mukhopadhyay S. Cellular signal transduction by anandamide and 2-arachidonoylglycerol. Chem Phys Lipids. 2000;108:53\u201370.","journal-title":"Chem Phys Lipids"},{"key":"898_CR48","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.pharmthera.2005.09.009","volume":"111","author":"M Oz","year":"2006","unstructured":"Oz M. Receptor-independent actions of cannabinoids on cell membranes: focus on endocannabinoids. Pharmacol Ther. 2006;111:114\u201344.","journal-title":"Pharmacol Ther"},{"key":"898_CR49","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/j.1471-4159.2006.04383.x","volume":"101","author":"DA Price","year":"2007","unstructured":"Price DA, Owens WA, Gould GG, Frazer A, Roberts JL, Daws LC, et al. CB1-independent inhibition of dopamine transporter activity by cannabinoids in mouse dorsal striatum. J Neurochem. 2007;101:389\u201396.","journal-title":"J Neurochem"},{"key":"898_CR50","doi-asserted-by":"publisher","first-page":"7895","DOI":"10.1073\/pnas.0511232103","volume":"103","author":"EJ Carrier","year":"2006","unstructured":"Carrier EJ, Auchampach JA, Hillard CJ. Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci USA. 2006;103:7895\u2013900.","journal-title":"Proc Natl Acad Sci USA"},{"key":"898_CR51","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1006\/bbrc.2002.6635","volume":"292","author":"K Monory","year":"2002","unstructured":"Monory K, Tzavara ET, Lexime J, Ledent C, Parmentier M, Borsodi A, et al. Novel, not adenylyl cyclase-coupled cannabinoid binding site in cerebellum of mice. Biochem Biophys Res Commun. 2002;292:231\u20135.","journal-title":"Biochem Biophys Res Commun"},{"key":"898_CR52","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1124\/mol.60.1.155","volume":"60","author":"CS Breivogel","year":"2001","unstructured":"Breivogel CS, Griffin G, Di Marzo V, Martin BR. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol. 2001;60:155\u201363.","journal-title":"Mol Pharmacol"},{"key":"898_CR53","doi-asserted-by":"publisher","first-page":"104319","DOI":"10.1016\/j.jpet.2026.104319","volume":"393","author":"E Ozkan","year":"2026","unstructured":"Ozkan E, Elmazoglu Z. The iron fist of nature: Cannabinoid derivatives alter iron homeostasis and activate ferroptotic pathways in glioblastoma cells. J Pharmacol Exp Ther. 2026;393:104319.","journal-title":"J Pharmacol Exp Ther"},{"key":"898_CR54","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.tiv.2019.02.009","volume":"57","author":"AG Silva","year":"2019","unstructured":"Silva AG, Lopes CFB, Carvalho J\u00fanior CG, Thom\u00e9 RG, Dos Santos HB, Reis R, et al. WIN55,212-2 induces caspase-independent apoptosis on human glioblastoma cells by regulating HSP70, p53 and Cathepsin D. Toxicol Vitro. 2019;57:233\u201343.","journal-title":"Toxicol Vitro"},{"key":"898_CR55","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/S0022-3565(24)38289-8","volume":"289","author":"CJ Hillard","year":"1999","unstructured":"Hillard CJ, Manna S, Greenberg MJ, DiCamelli R, Ross RA, Stevenson LA, et al. Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J Pharmacol Exp Ther. 1999;289:1427\u201333.","journal-title":"J Pharmacol Exp Ther"},{"key":"898_CR56","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S0026-895X(25)10492-6","volume":"48","author":"CC Felder","year":"1995","unstructured":"Felder CC, Joyce KE, Briley EM, Mansouri J, Mackie K, Blond O, et al. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol. 1995;48:443\u201350.","journal-title":"Mol Pharmacol"},{"key":"898_CR57","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1046\/j.1471-4159.1998.70010417.x","volume":"70","author":"SJ Gatley","year":"1998","unstructured":"Gatley SJ, Lan R, Volkow ND, Pappas N, King P, Wong CT, et al. Imaging the brain marijuana receptor: development of a radioligand that binds to cannabinoid CB1 receptors in vivo. J Neurochem. 1998;70:417\u201323.","journal-title":"J Neurochem"},{"key":"898_CR58","doi-asserted-by":"publisher","first-page":"1235255","DOI":"10.3389\/fphar.2023.1235255","volume":"14","author":"B Benredjem","year":"2023","unstructured":"Benredjem B, Pineyro G. A type II cannabis extract and a 1:1 blend of \u2206(9)-tetrahydrocannabinol and cannabidiol display distinct antinociceptive profiles and engage different endocannabinoid targets when administered into the subarachnoid space. Front Pharmacol. 2023;14:1235255.","journal-title":"Front Pharmacol"},{"key":"898_CR59","doi-asserted-by":"publisher","first-page":"1048836","DOI":"10.3389\/fpsyt.2022.1048836","volume":"13","author":"RC Kevin","year":"2022","unstructured":"Kevin RC, Cairns EA, Boyd R, Arnold JC, Bowen MT, McGregor IS, et al. Off-target pharmacological profiling of synthetic cannabinoid receptor agonists including AMB-FUBINACA, CUMYL-PINACA, PB-22, and XLR-11. Front Psychiatry. 2022;13:1048836.","journal-title":"Front Psychiatry"},{"key":"898_CR60","doi-asserted-by":"publisher","first-page":"24845","DOI":"10.1074\/jbc.M114.557025","volume":"289","author":"RB Laprairie","year":"2014","unstructured":"Laprairie RB, Bagher AM, Kelly ME, Dupr\u00e9 DJ, Denovan-Wright EM. Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons. J Biol Chem. 2014;289:24845\u201362.","journal-title":"J Biol Chem"},{"key":"898_CR61","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/glia.20108","volume":"49","author":"WS Sheng","year":"2005","unstructured":"Sheng WS, Hu S, Min X, Cabral GA, Lokensgard JR, Peterson PK. Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes. Glia. 2005;49:211\u20139.","journal-title":"Glia"},{"key":"898_CR62","doi-asserted-by":"publisher","first-page":"32879","DOI":"10.1074\/jbc.M603220200","volume":"281","author":"NA Jeske","year":"2006","unstructured":"Jeske NA, Patwardhan AM, Gamper N, Price TJ, Akopian AN, Hargreaves KM. Cannabinoid WIN 55,212-2 regulates TRPV1 phosphorylation in sensory neurons. J Biol Chem. 2006;281:32879\u201390.","journal-title":"J Biol Chem"},{"key":"898_CR63","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1248\/bpb.b25-00023","volume":"48","author":"K Mori","year":"2025","unstructured":"Mori K, Togo A, Ohta K, Asahi T, Nozaki C, Kataoka K. CB1 Receptor Agonist ACEA Resists ER Stress-Mediated Apoptosis via CB1R-Independent Mechanism. Biol Pharm Bull. 2025;48:769\u201381.","journal-title":"Biol Pharm Bull"},{"key":"898_CR64","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.neuint.2010.03.007","volume":"56","author":"ML De Jes\u00fas","year":"2010","unstructured":"De Jes\u00fas ML, Hostalot C, Garibi JM, Sall\u00e9s J, Meana JJ, Callado LF. Opposite changes in cannabinoid CB1 and CB2 receptor expression in human gliomas. Neurochem Int. 2010;56:829\u201333.","journal-title":"Neurochem Int"},{"key":"898_CR65","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1186\/s12885-018-4496-1","volume":"18","author":"MI Khan","year":"2018","unstructured":"Khan MI, Soboci\u0144ska AA, Brodaczewska KK, Zielniok K, Gajewska M, Kieda C, et al. Involvement of the CB(2) cannabinoid receptor in cell growth inhibition and G0\/G1 cell cycle arrest via the cannabinoid agonist WIN 55,212-2 in renal cell carcinoma. BMC Cancer. 2018;18:583.","journal-title":"BMC Cancer"},{"key":"898_CR66","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s12934-022-01914-1","volume":"21","author":"M Saumell-Esnaola","year":"2022","unstructured":"Saumell-Esnaola M, Elejaga-Jimeno A, Echeazarra L, Borrega-Rom\u00e1n L, Barrondo S, L\u00f3pez de Jes\u00fas M, et al. Design and validation of recombinant protein standards for quantitative Western blot analysis of cannabinoid CB(1) receptor density in cell membranes: an alternative to radioligand binding methods. Microb Cell Fact. 2022;21:192.","journal-title":"Microb Cell Fact"},{"key":"898_CR67","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1002\/glia.20983","volume":"58","author":"N Stella","year":"2010","unstructured":"Stella N. Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia. 2010;58:1017\u201330.","journal-title":"Glia"},{"key":"898_CR68","first-page":"100888","volume":"43","author":"B Chen","year":"2025","unstructured":"Chen B, Alder J. A systematic review of immunotherapies in combination with temozolomide as treatment for glioblastoma. Cancer Treat Res Commun. 2025;43:100888.","journal-title":"Cancer Treat Res Commun"},{"key":"898_CR69","doi-asserted-by":"crossref","unstructured":"Jeon J, Lee S, Kim H, Kang H, Youn H, Jo S, et al. Revisiting platinum-based anticancer drugs to overcome gliomas. Int J Mol Sci. 2021;22.","DOI":"10.3390\/ijms22105111"},{"key":"898_CR70","doi-asserted-by":"publisher","first-page":"e6261","DOI":"10.1097\/MD.0000000000006261","volume":"96","author":"Y Wang","year":"2017","unstructured":"Wang Y, Kong X, Guo Y, Wang R, Ma W. Continuous dose-intense temozolomide and cisplatin in recurrent glioblastoma patients. Medicine. 2017;96:e6261.","journal-title":"Medicine"},{"key":"898_CR71","doi-asserted-by":"publisher","first-page":"e2532187123","DOI":"10.1073\/pnas.2532187123","volume":"123","author":"H Kaanoglu","year":"2026","unstructured":"Kaanoglu H, Akyel YK, Adefolaju A, Valdivia A, Higgins D, Sellers RS, et al. Combinatorial treatment of glioblastoma with temozolomide (TMZ) plus 5-ethynyl-2\u2019-deoxyuridine (EdU). Proc Natl Acad Sci USA. 2026;123:e2532187123.","journal-title":"Proc Natl Acad Sci USA"},{"key":"898_CR72","first-page":"1700","volume":"15","author":"A Abderam","year":"2025","unstructured":"Abderam A, Yazdi P, Abbasinezhad-Moud F, Shirazinia M, Pouyamanesh G, Shojaee M, et al. Synergistic effects of oxypeucedanin and temozolomide on viability, proliferation, apoptosis, and migration of T98G malignant glioblastoma cells. Avicenna J Phytomed. 2025;15:1700\u201313.","journal-title":"Avicenna J Phytomed"},{"key":"898_CR73","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1136\/spcare-2025-005759","volume":"16","author":"T Sosorburam","year":"2025","unstructured":"Sosorburam T. Adverse events and cannabinoid use in cancer management: systematic review. BMJ Support Palliat Care. 2025;16:20\u20137.","journal-title":"BMJ Support Palliat Care"},{"key":"898_CR74","doi-asserted-by":"crossref","unstructured":"Reddy AC, Hampton JM, Park SJ, Dickerson F, Chewning B, Schmitz N, et al. The effects of tetrahydrocannabinol and cannabidiol on sleep in cancer patients. Clin Transl Oncol. 2025.","DOI":"10.1007\/s12094-025-04069-8"},{"key":"898_CR75","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1007\/s11912-025-01695-x","volume":"27","author":"I Creang\u0103-Murariu","year":"2025","unstructured":"Creang\u0103-Murariu I, Rezu\u0219 II, Karami R, Rancz A, Zolcs\u00e1k \u00c1, Engh MA, et al. Indications of Cannabinoids for the Palliation of Cancer-Associated Symptoms: A Systematic Review and Meta-Analysis. Curr Oncol Rep. 2025;27:1080\u201396.","journal-title":"Curr Oncol Rep"},{"key":"898_CR76","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/s41593-025-01891-9","volume":"28","author":"KA Dudek","year":"2025","unstructured":"Dudek KA, Paton SEJ, Binder LB, Collignon A, Dion-Albert L, Cadoret A, et al. Astrocytic cannabinoid receptor 1 promotes resilience by dampening stress-induced blood-brain barrier alterations. Nat Neurosci. 2025;28:766\u201382.","journal-title":"Nat Neurosci"},{"key":"898_CR77","doi-asserted-by":"publisher","first-page":"110366","DOI":"10.1016\/j.neuropharm.2025.110366","volume":"270","author":"Q Zhang","year":"2025","unstructured":"Zhang Q, Huang W, Li T, Wang X, Lai X, Hu W, et al. \u2206(9)-tetrahydrocannabinol induces blood-brain barrier disruption: Involving the activation of CB1R and oxidative stress. Neuropharmacology. 2025;270:110366.","journal-title":"Neuropharmacology"},{"key":"898_CR78","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1089\/can.2021.0101","volume":"7","author":"K Hagan","year":"2022","unstructured":"Hagan K, Varelas P, Zheng H. Endocannabinoid System of the Blood-Brain Barrier: Current Understandings and Therapeutic Potentials. Cannabis Cannabinoid Res. 2022;7:561\u20138.","journal-title":"Cannabis Cannabinoid Res"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-026-00898-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-026-00898-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-026-00898-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:02:46Z","timestamp":1788962566000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-026-00898-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":78,"alternative-id":["898"],"URL":"https:\/\/doi.org\/10.1007\/s43440-026-00898-8","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"assertion":[{"value":"16 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Institutional review board statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No AI or AI-assisted technologies were used in the preparation of this manuscript. This is human-authored article.","order":4,"name":"Ethics","label":"Artificial intelligence (AI) in the writing process","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}